Yinuo Pang

1.4k total citations
38 papers, 568 citations indexed

About

Yinuo Pang is a scholar working on Immunology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Yinuo Pang has authored 38 papers receiving a total of 568 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 9 papers in Genetics and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Yinuo Pang's work include Inflammatory Bowel Disease (7 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Pharmaceutical studies and practices (7 papers). Yinuo Pang is often cited by papers focused on Inflammatory Bowel Disease (7 papers), Psoriasis: Treatment and Pathogenesis (7 papers) and Pharmaceutical studies and practices (7 papers). Yinuo Pang collaborates with scholars based in United States, Germany and Switzerland. Yinuo Pang's co-authors include Amit Khatri, Ahmed A. Suleiman, Mohamed I. A. Othman, Ronilda D’Cunha, Peter R. Byron, Masahiro Sakagami, Marion Dahlke, Mukul Minocha, Kori Wallace and Jasmina Kalabic and has published in prestigious journals such as Circulation, Antimicrobial Agents and Chemotherapy and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Yinuo Pang

36 papers receiving 552 citations

Peers

Countries citing papers authored by Yinuo Pang

Since Specialization

Citations

This map shows the geographic impact of Yinuo Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yinuo Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yinuo Pang more than expected).

Fields of papers citing papers by Yinuo Pang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yinuo Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yinuo Pang. The network helps show where Yinuo Pang may publish in the future.

Co-authorship network of co-authors of Yinuo Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Yinuo Pang. A scholar is included among the top collaborators of Yinuo Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yinuo Pang. Yinuo Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low-dose rituximab in lupus enteritis: a comparative study on its efficacy in modulating mucosal immunity and reducing inflammation 2025 ·Arthritis Research & Therapy ·Ying Liu, Yinuo Pang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Nailfold videocapillaroscopy findings are associated with IIM subtypes and IFN activation 2025 ·Arthritis Research & Therapy ·(unknown), Jia Shi, Yinuo Pang, Shuang Zhou, Jinjing Liu, Chanyuan Wu, (unknown), Xiaofeng Zeng, Qian Wang	0
3	Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), Ahmed A. Suleiman, Ronilda D’Cunha, Sven Mensing, (unknown), Yinuo Pang	5
4	Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease 2024 ·Clinical Pharmacokinetics ·Ronilda D’Cunha, (unknown), Jasmina Kalabic, (unknown), Adi Lahat, Yinuo Pang	1
5	Risankizumab: Mechanism of action, clinical and translational science 2024 ·Clinical and Translational Science ·Yinuo Pang, Ronilda D’Cunha, (unknown), Geertruida M. Veldman, Valerie Pivorunas, Kori Wallace	20
6	A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants 2023 ·British Journal of Clinical Pharmacology ·Ronilda D’Cunha, H. Küpper, Dilek Arikan, (unknown), David Carter, Jonas Blaes, Melanie C. Ruzek, Yinuo Pang	6
7	Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up 2023 ·Journal of the American Academy of Dermatology ·Kim Papp, Andrew Blauvelt, L. Puig, Mamitaro Ohtsuki, Stefan Beissert, Melinda Gooderham, (unknown), Jie Liu, Tianshuang Wu, (unknown), (unknown), Ramon Espaillat, (unknown), Ahmed M. Soliman, Yinuo Pang, Michael M. Chen, Mark Lebwohl	30
8	Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease 2023 ·Advances in Therapy ·Edward V. Loftus, Jenny Griffith, Ezequiel Neimark, Alexandra Song, Kori Wallace, (unknown), (unknown), Rachel Byrne, Kristina Kligys, Yinuo Pang, Xiaomei Liao, Jasmina Kalabic, Marla C. Dubinsky	9
9	Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease 2023 ·Clinical Therapeutics ·Yinuo Pang, Ronilda D’Cunha, Afroz S. Mohammad, (unknown), (unknown), Jasmina Kalabic, (unknown), Sai Nudurupati, Kori Wallace, (unknown), (unknown), (unknown), (unknown), Patrick Marroum	5
10	Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial 2022 ·Arthritis & Rheumatology ·Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich, (unknown), Su Chen, Yang� Yang, Dilek Arikan, Ronilda D’Cunha, Yinuo Pang, H. Küpper, Timothy R. D. J. Radstake, Howard Amital	31
11	Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial 2020 ·Cardiovascular Research ·David Corcoran, Aleksandra Radjenovic, Ify Mordi, Sheraz A. Nazir, Simon Wilson, Markus Hinder, Denise P. Yates, (unknown), (unknown), Margaret F. Prescott, (unknown), Yinuo Pang, Niko Tzemos, Scott Semple, David E. Newby, Gerry P McCann, Iain Squire, Colin Berry	6
12	Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes 2019 ·Journal of Pharmacology and Experimental Therapeutics ·François Pognan, Philippe Couttet, (unknown), (unknown), Yinuo Pang, Ronenn Roubenoff, Esther Sutter, Yoav Timsit, (unknown), (unknown), Gaëtane Woerly, Armin Wolf, U. Schramm	17
13	Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients 2019 ·Clinical Pharmacokinetics ·Yinuo Pang, Amit Khatri, Ahmed A. Suleiman, Mohamed I. A. Othman	23
14	Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis 2018 ·Clinical Pharmacokinetics ·Amit Khatri, (unknown), Anne Camez, Stanislav Ignatenko, Yinuo Pang, Mohamed I. A. Othman	26
15	LATE BREAKING CLINICAL TRIAL (JCS 2015) : Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure 2015 ·Circulation ·Naoki Sato, Wataru Takahashi, Atsushi Hirayama, Masayoshi Ajioka, Naoto Takahashi, Kaoru Okishige, (unknown), Akio Maki, (unknown), Ursula Ebinger, Masayuki Yamaguchi, Yinuo Pang, Hiroki Matsumoto, Masatoshi Kawana	10
16	Effects of PEGylation and Immune Complex Formation on the Pharmacokinetics and Biodistribution of Recombinant Interleukin 10 in Mice 2011 ·Drug Metabolism and Disposition ·Hamsell M. Alvarez, On‐Yee So, (unknown), (unknown), Huiping Ma, Yaoli Song, Yinuo Pang, Melinda Marian, Enrique Escandón	18
17	Pharmacokinetics of 23-Epi-26-Deoxyactein in Women After Oral Administration of a Standardized Extract of Black Cohosh 2009 ·Clinical Pharmacology & Therapeutics ·Richard B. van Breemen, (unknown), Suzanne Banuvar, L.P. Shulman, Yinuo Pang, Yang Tao, Dejan Nikolić, (unknown), Daniel S. Fabricant, Shao‐Nong Chen, Samad Hedayat, Judy L. Bolton, Guido F. Pauli, C E Piersen, E C Krause, Stacie Geller, Norman R. Farnsworth	26
18	Insulin Self-association: Effects on Lung Disposition Kinetics in the Airways of the Isolated Perfused Rat Lung (IPRL) 2007 ·Pharmaceutical Research ·Yinuo Pang, Masahiro Sakagami, Peter R. Byron	9
19	The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: Implications of metabolism and regional deposition 2005 ·European Journal of Pharmaceutical Sciences ·Yinuo Pang, Masahiro Sakagami, Peter R. Byron	26
20	[Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers]. 2003 ·PubMed ·(unknown), Yinuo Pang, Zhixiao Wang, (unknown), Qiang Cheng, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact